RT Journal Article
SR Electronic
T1 Effect of New Oxicam Derivatives on Efflux Pumps Overexpressed in Resistant a Human Colorectal Adenocarcinoma Cell Line
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2835
OP 2840
VO 35
IS 5
A1 KAMILA ŚRODA-POMIANEK
A1 OLGA WESOŁOWSKA
A1 BERENIKA SZCZĘŚNIAK-SIĘGA
A1 BARTOSZ PUŁA
A1 PIOTR DZIĘGIEL
A1 JADWIGA MANIEWSKA
A1 WIESŁAW MALINKA
A1 ANNA PALKO-ŁABUZ
A1 KRYSTYNA MICHALAK
YR 2015
UL http://ar.iiarjournals.org/content/35/5/2835.abstract
AB Background: Oxicams are non-steroidal anti-inflammatory drugs (NSAIDs). Antitumor potential of NSAIDs has often been reported in literature. We studied antitumor activity of newly synthesized oxicam derivatives (PR17 and PR18) against doxorubicin-sensitive and resistant human colorectal adenocarcinoma cells (LoVo and LoVo/Dx). Materials and Methods: The cytotoxicity of oxicam derivatives alone and in combination with doxorubicin was assessed. Inhibition of P-glycoprotein (ABCB1) transport activity was monitored by flow cytometry. Expression of ABCB1 gene was analyzed by semi-quantitative reverse transcription PCR, while ABCB1 protein expression was assessed by western blotting. Results: Oxicam derivative PR18 was more cytotoxic to cancer cells than PR17. PR18 was observed to sensitize LoVo/Dx cells to doxorubicin and was identified as an effective multidrug resistance modulator. Additionally, ABCB1 expression was reduced in the presence of PR18. Conclusion: PR18 was identified as an effective modulator in LoVo/Dx resistant human colorectal adenocarcinoma cells which overexpressed ABCB1 efflux pump.